Chronic kidney disease is a common problem in aging cats. The cat’s diseased kidneys often do not produce enough erythropoietin hormone leading to a deficiency of red blood cells (anemia). Anemia contributes significantly to the morbidity of the cats with chronic renal failure. A therapeutic solution available to overcome this problem is the administration of commercially available human erythropoietin to cats with chronic renal disease. Generally, this treatment is effective for a limited period of time, but eventually fails as a result of an immunologic reaction against the administered human erythropoietin. The researchers propose a gene therapy system that will shuttle the natural feline erythropoietin gene into cat cells. Ideally, treated cells will express natural feline erythropoietin. This study describes an in vitro proof of concept pilot project for a subsequent in vivo gene therapy trial involving anemic cats with renal failure. Results from this study could contribute significantly to the overall health and well-being of cats with chronic anemia associated with renal disease.